Skip to main content

Table 2 The age distribution and hospitalization with different serotypes in 2013–2015, 2017–2019 and 2020–2022 of Chengdu area

From: Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013–2022

 

2013–2015

2017–2019

2020–2022

P1 value

P2 value

EV-A71.N

     

 Age group, month n (%)

   

 < 0.001

  0–11

99 (5.78)

12 (8.00)

  

  12–23

434 (25.34)

27 (18.00)

  

  24–47

893 (52.13)

58 (38.67)

  

  > 48

287 (16.75)

53 (35.33)

  

 In outpatient, n (%)

     

  Inpatient

332 (19.38)

9 (6.00)

  

  Outpatient

1381 (80.62)

141 (94.00)

  

CV-A16.N

1759

891

152

  

 Age group,month n (%)

   

 < 0.001

0.225

  0–11

106 (6.03)

56 (6.29)

7 (4.61)

  

  12–23

457 (25.98)

193 (21.66)

31 (20.39)

  

  24–47

942 (53.55)

369 (41.41)

47 (30.92)

  

  ≥ 48

254 (14.44)

273 (3064)

67 (44.08)

  

In outpatient, n(%)

   

0.016

0.285

  Inpatient

84 (4.78)

25 (2.81)

2 (1.32)

  

  Outpatient

1675 (95.22)

866 (97.19)

150 (98.68)

  

Other enterovirus 1, N

9127

7175

3196

  

 Age group, month n (%)

   

 < 0.001

 < 0.001

 0–11

1130 (12.38)

1001 (13.95)

365 (11.42)

  

 12–23

3438 (37.67)

2648 (36.91)

   

 24–47

3823 (41.89)

2678 (37.32)

   

  > 48

736 (8.06)

848 (11.82)

   

 In outpatient, n(%)

   

 < 0.001

0.016

  Inpatient

645 (7.07)

356 (4.96)

124 (3.88)

  

  Outpatient

8482 (92.93)

6819 (95.04)

3072 (96.12)

  
  1. Other enterovirus 1: No-EV-A71 and No-CY-A16 enterovirus; P1 value: the data in 2017–2019 compared with 2013–2015; P2 value: the data in 2020–2022 compared with 2017–2019; The chi-square test was used for all analysis in the Table 2